Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

Today, 36 million people in the European Union (EU) and 30 million in the US with a rare disease face the harsh reality of a ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid ...

The first company to take up residence in Bayer Co.Lab Berlin – initially located on the group's pharma headquarters site in ...

A strategy for women's health in England was published in 2022 under the previous Conservative government, led at the time by ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-Elect has ...

Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare Disorders ...

Advanz won a temporary reprieve in September after the General Court of the European Union ordered a suspension of the EC's ...

In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

“It’s a really exciting time, not just for NWEH, but also for the future of clinical trials in the UK. If successful, this ...

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's gene therapy for the rare ...

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an ...